Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) was down 8.3% during mid-day trading on Thursday . The company traded as low as $15.52 and last traded at $15.76, with a volume of 285,949 shares traded. The stock had previously closed at $17.19.

A number of equities research analysts have recently issued reports on EIGR shares. Jefferies Group reissued a “buy” rating on shares of Eiger BioPharmaceuticals in a report on Monday, May 16th. Wedbush started coverage on shares of Eiger BioPharmaceuticals in a report on Wednesday, June 1st. They issued an “outperform” rating and a $36.00 price target on the stock. Zacks Investment Research downgraded shares of Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, June 7th. Finally, Oppenheimer Holdings Inc. started coverage on shares of Eiger BioPharmaceuticals in a report on Tuesday, July 5th. They issued an “outperform” rating and a $34.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Eiger BioPharmaceuticals has an average rating of “Buy” and an average target price of $34.50.

The firm has a 50-day moving average of $18.91 and a 200-day moving average of $18.53. The company’s market cap is $112.53 million.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last released its quarterly earnings data on Wednesday, August 10th. The company reported ($1.87) EPS for the quarter, missing the consensus estimate of ($1.17) by $0.70. On average, equities analysts anticipate that Eiger BioPharmaceuticals Inc. will post ($8.96) EPS for the current year.

In other Eiger BioPharmaceuticals news, insider James P. Shaffer acquired 3,125 shares of Eiger BioPharmaceuticals stock in a transaction that occurred on Thursday, August 18th. The stock was bought at an average cost of $15.70 per share, for a total transaction of $49,062.50. Following the acquisition, the insider now owns 5,620 shares of the company’s stock, valued at $88,234. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James H. Welch acquired 2,500 shares of Eiger BioPharmaceuticals stock in a transaction that occurred on Wednesday, June 22nd. The stock was acquired at an average price of $19.80 per share, with a total value of $49,500.00. Following the completion of the acquisition, the chief financial officer now directly owns 2,000 shares in the company, valued at approximately $39,600. The disclosure for this purchase can be found here.

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.